ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating
CEO & Managing Director, Dr Tony Keating
Source: Business News
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ResApp Health (RAP) has teamed up with Phenix Health to integrate their health-centric smartphone apps
  • Phenix Health is an online virtual clinic, while ResApp has developed a health app to detect respiratory diseases
  • From the beginning of COVID-19, Phenix said it has seen a 30 per cent month-on-month increase in the number of consultations
  • ResApp’s software will enhance Phenix’s virtual clinics
  • ResApp is up 13 per cent on the market this morning, trading at 7.8¢ per share

ResApp Health (RAP) has teamed up with Phenix Health to integrate their smartphone apps.

Phenix Health is mobile clinic software developers and provides an online virtual health clinic, called telehealth.

ResApp has developed a respiratory health app, ResAppDx-EU.

ResAppDx-EU is a software application used by clinicians to diagnose the most common respiratory diseases. The software uses machine learning algorithms to analyse the patient.

Phenix CEO Dr Gillian Alexis says telehealth is emerging as a key tool in tackling the COVID-19 pandemic and the company is well-positioned to provide a valuable service to the Australian community.

Phenix provides video consultations to patients across Australia and, since the beginning of this crisis, it has seen a 30 per cent month-on-month increase in the number of consultations.

“Our virtual clinic can be accessed nationwide through HealthEngine or directly via our downloadable app, and for patients told to self-isolate for possible COVID-19,
these consultations are reimbursable under the MBS scheme (medicare benefits scheme),” Gillian said.

“Phenix knows that implementing a telehealth service for patients must go beyond the limits of consumer video chat platforms like Skype which is why we are working with ResApp to bring their advanced diagnostic tool to our platform,” he added.

ResApp currently has a CE marking from the European Union and Therapeutics Goods Administration in Australia for the app. However, it was recently denied approval by the U.S. Food and Drug Administration.

ResApp CEO Tony Keating is excited to be working with Phenix to enhance its service.

“ResAppDx-EU offers the only solution to accurately diagnose respiratory conditions through telehealth and will provide telehealth clinicians with a remote testing capability to help manage the COVID-19 pandemic,” Tony told the market.

“By assisting general practitioners (GPs) to evaluate patient symptoms during a telehealth consultation, in particular, if an infection has reached the patient’s lungs, GPs will be better able to determine whether a patient should attend a hospital or clinic for additional care, conserving strained healthcare resources,” he added.

The companies will be working together for the next three months. During this time, ResApp and Phenix are negotiating a fee-per-test payment model using ResAppDx-EU on the Phenix App.

ResApp is up 13 per cent on the market this morning, trading at 7.8¢ per share at 11:10 am AEDT.

RAP by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…